TRIUMPH-4 (28.7% weight loss, knee OA population, December 2025), TRIUMPH-1 (28.3%, general obesity, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c, 16.8% weight loss, June 2026), TRIUMPH-2 (20.8% weight loss, obesity + diabetes, July 23, 2026), and TRIUMPH-3 (22.6% weight loss, obesity + cardiovascular disease, July 23, 2026) have all reported positive results
Open communication ensures your semaglutide therapy remains safe and effective, and your treatment can be adjusted or supplemented to restore your energy and momentum
Semaglutide, the active ingredient in medications like Wegovy, Ozempic, and Rybelsus, works by mimicking a naturally occurring hormone in your body called glucagon-like peptide-1 (GLP-1)
Weight Loss and Metabolic Benefits: Obesity is a major risk factor for cardiovascular disease